That is essential, since the way a protein in the human body folds figures out if a pharmaceutical will be able to bind to that protein and be reliable. To put it simply, we have to understand how these proteins fold if we want a drug to work. Historically, this has been an experimental procedure (jeff brown stock picks 2021). Today, Alpha, Fold can predict protein folding with 92. 4% accuracy. That's going to make it much simpler to create drugs that do what they're created to do. This was a development nearly no one observed. But it's going to have extensive implications for curing illness. I anticipate that Alpha, Fold will be 98% accurate by the end of 2021.
And, of course, there will be lots of investment opportunities in this space, too. Moving topics It's going to be a great year for bitcoin. I'm bullish on it in 2021 (jeff brown predictions 2021). That stated, I still think bitcoin will continue to be unstable. We're close to all-time highs. I would not be shocked if it drew back possibly significantly before going greater - tech predictions. I've been covering bitcoin for a long time now. Among the very first research reports I ever published was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that initial suggestion, I titled my report "What's the Big Offer With Bitcoin?" That shows you where the discussion was at the time. We were mainly informing readers. But that's not the big concern anymore. Now we're seeing institutional cash lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, niche business. Mass, Mutual is a relied on 170-year-old institution. So believe about that. In five years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
Which's a huge reason I'm bullish on it this year. first lady. Regards, Jeff Brown, Editor, The Bleeding Edge I have a reward prediction 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These companies raised a total of $172 billion. That's an all-time high beating the previous annual record by 43%. I forecast 2021 will be another record year in IPOs. There are so lots of great private business on the brink of hitting the public markets And I've been dealing with a new way for you to invest even before these companies go public.
This opportunity has actually been developing over the last couple of years. I can't wait to inform you all about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to discover out all the details. Go right here to book your spot totally free.
Emma Walsh here, handling editor of the Diary. Regular Journal readers know that tech isn't our usual beat (jeff brown biotech stock). And when it pertains to tech investing, we leave it to the specialists. The good news is, we have numerous such experts in our Rolodex. Our associate Jeff Brown will be familiar to our longtime readers. He is among the most accomplished tech investing experts we understand (jeff brown stock market prediction). In truth, he had numerous triple-digit returns in his Brownstone Research portfolios last year. Here's what Jeff thinks the tech sector will bring us in 2021 Each year, I like to have a look at the huge picture and predict what's just around the corner.
That consists of things like 5G networks, biotech, artificial intelligence, and a lot more. These patterns are experiencing exponential development and developing incredible opportunities for financiers. I want to ensure all our readers are prepared for what's next. And with that in mind, let me draw the image of what I see can be found in the next 12 months Our brand-new 5G (fifth-generation) cordless networks are a topic I have actually been covering for years now. future report. However in spite of what lots of readers may believe, this is a pattern that's simply getting started. Although the COVID-19 pandemic disrupted supply chains in 2015, an impressive 250 million 5G-enabled devices were still offered.
And all of this ultimately led to Apple delaying the release of the 5G-enabled i, Phone 12 by two months (angel investor). Losing 2 months of manufacturing and sales truly affects the number of 5G devices are sold in the calendar year. When you consider all of that, offering 250 million systems is remarkable. More notably, the delays triggered by the pandemic produced a lots of suppressed demand. And that demand is now going to be pressed into 2021. In truth, I forecast that more than 500 million 5G devices will be shipped in 2021 - jeff brown biotech stock pick for 2020. And that's not my only 5G forecast When I've spoken about 5G in the past, I have actually described its 3 different stages.
In Phase Two, 5G devices go on sale. 5G phones and other products start to reach customers. And in Phase 3, 5G services begin to be used (diplomatic relations). That's when we start to see applications working on 5G networks. Believe of things like huge multiplayer video games over a mobile phone. That's not possible with 4G. It will be with 5G. And my 2nd 5G prediction for 2021 is that we will start Stage 3 by this summer season. This begins something of a virtuous cycle: Many people do not really care about the technology. However they will care if there are exciting applications that can just be accessed with a 5G phone.
That results in more 5G apps being established. In truth, 5G is going to open a suite of amazing applications: self-driving automobiles, the Internet of Things, robotic surgery, and more. All of these technologies require 5G. The financial investment chances going forward will be massive. Stepping away from 5G, the next crucial technology I predict in 2021 is CRISPR hereditary editing. CRISPR stands for "clustered regularly interspaced short palindromic repeat." It's a mouthful. But it is among the most amazing advancements in biotechnology. At a high level, CRISPR is a technology that can modify our genetic makeup as if it were software application.
The program can crash or not operate properly. CRISPR uses a comparable concept however with our hereditary code. "Typos" in our genome can lead to illness. CRISPR can correct these "typos." For several years, CRISPR was mostly a specific niche technology that wasn't well understood. And throughout that time, there were really only three business operating in this area. However things are altering. CRISPR is no longer just theoretical. We're seeing actual results. We're dealing with diseases and seeing that this technology simply works. And as an outcome, a "second crop" of early-stage CRISPR business is going public and providing amazing returns. This entire industry is effectively a greenfield chance.
There's space for lots of companies to exist in this area. jeff brown tech stock 2021. And there will be more. That's my prediction for CRISPR in 2021. I anticipate that 2 or three more genetic editing business will hold their IPOs. Sticking to biotechnology, we are seeing remarkable things occurring at the merging of biotech and expert system (AI). Google's AI subsidiary, Deep, Mind, just announced at the end of 2020 that its latest Alpha, Fold software can properly forecast the folding of a protein based exclusively on its amino acid series with 92. 4% precision. That is very important since the method a protein in the human body folds identifies if a pharmaceutical will be able to bind to that protein and work.
Historically, this has been an experimental process. Today, Alpha, Fold can forecast protein folding with 92. 4% accuracy. That's going to make it much easier to create drugs that do what they're designed to do. And here's my next prediction. I predict that Alpha, Fold will be 98% precise by the end of 2021. And we will see not just one however a number of drug treatments produced utilizing this technology. This was one of those advancements that almost no one saw. But it's going to have profound implications for treating disease. And, naturally, there will be a lot of financial investment opportunities in this space, too.
It's going to be an excellent year for bitcoin. I'm bullish on it in 2021. That said, I still believe bitcoin will continue to be volatile. We're close to all-time highs. I would not be amazed if it drew back perhaps substantially prior to going greater. I've been covering bitcoin for a long period of time now. Among the first research study reports I ever released was on bitcoin - last year. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on investment for anyone who followed my recommendation. However at the time of that initial recommendation, I entitled my report, "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time.
However no one is asking that concern any longer. Now, we're seeing institutional money finally taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, niche business. brownstone research. Mass, Mutual is a 150-year-old organization. So believe about that. In 5 years, we went from educating readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a huge reason why I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another perk prediction In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown is worth about $27. 5 million and declares the information is up to date as of February 2021, but we might not individually confirm this claim. Provided Jeff Brown's past, he likely has a considerable net worth, however we can't hammer down a precise figure at this moment. Brown is best known for his sage-like capability to choose winning innovation stocks. He invested more than 25 years looking into technology business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's comprehensive experience provides him an excellent viewpoint on the marketplace. He's always on the hunt for new opportunities, and he shares a number of his finest picks in the Near Future Report.
That's high praise, but it's not absurdly reasoned. Brown has an excellent track record as a stock-picker, and he effectively anticipated some of the greatest economic events of the past twenty years. Although he does not appear to release his choices to the general public, the service's success is a direct sign of Brown's stock-picking expertise. Nobody on Wall Street gets it right each time, however Jeff Brown's accurate predictions have actually earned him legions of dedicated fans. That states a lot about his capability. The Near Future Report is released by Brownstone Research study, a prominent monetary research study publisher. Brownstone Research study provides a number of research services with a wide array of expertises - biotech stocks.
The business is also associated with Bonner & Partners, another well-respected research publisher - jeff brown biotech genome sequencing. On its site, Brownstone says its objective is to offer retail investors with professional-grade research: "For too long, the finest investment research study has not been offered to specific investors. It has been generally reserved for investment banks, hedge funds, private equity, and high-net-worth customers. jeff brown top biotech 2020. The mission of Brownstone Research is to make that sort of exclusive research study readily available to any financiers seeking to get an edge in the marketplaces. The goal is basic to deliver unique and profitable investment research found no place else." -Brownstone Research website excerpt from the Jeff Brown is the creator of Brownstone Research, and he also functions as the firm's Chief Investment Analyst.
With Brown guiding the ship, Brownstone Research is a powerhouse publisher with lots to use its customers. After decades of constant success at the helm of top-tier companies like Tesla and Space, X, Elon Musk is a family name throughout the majority of America. If you know even a little bit about the marketplace, you understand that he has a reputation as a King Midas of sorts. jeff brown 1 biotech company. Everything he touches relies on gold! Jeff is well aware of Elon Musk's executive expertise, so he always has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next big project.
In fact, Brown believes S.A.V. jeff brown genetic sequencer stock. could be "the most significant trend of the 2020s, and he's not alone. Take a look at these quotes from other well-known S.A.V. bulls: Elon's next huge act will be weding 2 cutting-edge innovations: expert system and electric cars and trucks. Musk hopes the combination will help him develop the first fully-autonomous, self-driving automobiles ever. It's absolutely nothing except the automotive industry's Holy Grail. As you know, electric cars and self-driving automobile stocks have been big this year, but the Wall Street machine has actually been huge on buzz without much concrete result. Despite a drastic boost in competitors over the previous few years, Brown still believes Musk has the best possibility of putting all of it together.
tech might be the magic string that connects everything together. S.A.V. means Shared Autonomous Lorry, and it might be the future of transportation. Basically, this technology would enable you to lease your car as an autonomous, self-driving taxi when you're not utilizing it. You merely leave the car and press a button on an app that tells the automobile to "sign up with the fleet." Next thing you know, you're unwinding on your sofa while your car shuttles ride-sharers around town. Best of all, you get to keep a substantial chunk of the earnings. It sounds ridiculous, but it might be closed than you think.